
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES224
The secondary endpoint analysis (ischaemic stroke and/or vascular death, all-cause stroke, non fatal events and rehospitalisation) showed no significant difference between the addition of aspirin to clopidogrel versus clopidogrel plus placebo, though rates were lower with aspirin than with placebo, added to clopidogrel. Level 1++

[@Diener_2004]

